Search results for "embolism"

showing 10 items of 457 documents

Validation of a Model for Identification of Patients at Intermediate to High Risk for Complications Associated With Acute Symptomatic Pulmonary Embol…

2015

For patients with acute symptomatic pulmonary embolism (PE), the Bova score classifies their risk for PE-related complications within 30 days after diagnosis. The original Bova score was derived from 2,874 normotensive patients with acute PE who participated in one of six prospective PE studies.We retrospectively assessed the validity of the Bova risk model in normotensive patients with acute PE diagnosed in an academic urban ED. Two clinician investigators used baseline data for the model's four prognostic variables to stratify patients into the three Bova risk stages (I-III) for 30-day PE-related complications. Intraclass correlation coefficient (ICC) and the κ statistic were used to asse…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyPrognostic variableIntraclass correlationBlood PressureCritical Care and Intensive Care MedicineRisk AssessmentHeart RateInternal medicine80 and overmedicineVentricular FunctionHumansStage (cooking)AgedRetrospective StudiesAged 80 and overFramingham Risk Scorebusiness.industryTroponin IReproducibility of ResultsRetrospective cohort studyMiddle AgedPrognosismedicine.diseasePulmonary embolismSurgeryAcute Disease; Aged; Aged 80 and over; Blood Pressure; Female; Heart Rate; Humans; Male; Middle Aged; Prognosis; Pulmonary Embolism; Reproducibility of Results; Retrospective Studies; Risk Assessment; Spain; Troponin I; Ventricular Function Right; Pulmonary and Respiratory Medicine; Critical Care and Intensive Care Medicine; Cardiology and Cardiovascular MedicineRightSpainAcute DiseaseCohortVentricular Function RightFemalePulmonary EmbolismCardiology and Cardiovascular MedicineRisk assessmentbusinessChest
researchProduct

Validation of N-terminal pro-brain natriuretic peptide cut-off values for risk stratification of pulmonary embolism

2014

The optimal N-terminal pro-brain natriuretic peptide (NT-proBNP) cut-off value for risk stratification of pulmonary embolism remains controversial. In this study we validated and compared different proposed NT-proBNP cut-off values in 688 normotensive patients with pulmonary embolism. During the first 30 days, 28 (4.1%) patients reached the primary outcome (pulmonary embolism-related death or complications) and 29 (4.2%) patients died. Receiver operating characteristic analysis yielded an area under the curve of 0.70 (0.60-0.80) for NT-proBNP. A cut-off value of 600 pg·mL(-1) was associated with the best prognostic performance (sensitivity 86% and specificity 50%) and the highest odds ratio…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyTime Factorsmedicine.drug_classVentricular Dysfunction Right030204 cardiovascular system & hematologyLogistic regressionRisk AssessmentSensitivity and Specificity03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicineNatriuretic Peptide BrainOdds RatiomedicineNatriuretic peptideHumansProspective Studies030212 general & internal medicineProspective cohort studyAgedbusiness.industryArea under the curveReproducibility of ResultsOdds ratioMiddle AgedPrognosismedicine.diseasePeptide Fragments3. Good healthPulmonary embolismTreatment OutcomeROC CurveEchocardiographyPredictive value of testsMultivariate AnalysisCardiologyFemalePulmonary EmbolismRisk assessmentbusinessBiomarkersEuropean Respiratory Journal
researchProduct

Identification of intermediate-risk patients with acute symptomatic pulmonary embolism

2014

The identification of normotensive patients with acute pulmonary embolism (PE) at high risk of adverse PE-related clinical events (i.e. intermediate-risk group) is a major challenge. We combined individual patient data from six studies involving 2874 normotensive patients with PE. We developed a prognostic model for intermediate-risk PE based on the clinical presentation and the assessment of right ventricular dysfunction and myocardial injury. We used a composite of PE-related death, haemodynamic collapse or recurrent PE within 30 days of follow-up as the main outcome measure. The primary outcome occurred in 198 (6.9%) patients. Predictors of complications included systolic blood pressure …

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyVentricular Dysfunction RightHemodynamicsBlood PressureRecurrenceRisk FactorsInternal medicineHeart rateOdds RatiomedicineHumansProspective StudiesProspective cohort studyAgedRetrospective StudiesAged 80 and overbusiness.industryHemodynamicsRetrospective cohort studyOdds ratioMiddle AgedDecision Support Systems ClinicalPrognosismedicine.diseaseSurgeryPulmonary embolismTreatment OutcomeBlood pressureCardiologyFemaleCardiomyopathiesPulmonary EmbolismbusinessComplicationEuropean Respiratory Journal
researchProduct

Risk stratification of normotensive pulmonary embolism: prognostic impact of copeptin

2015

The prognostic value of copeptin, the C-terminal fragment of the precursor protein of vasopressin which is released upon stress, and hypotension in pulmonary embolism is unknown, especially if combined with biomarkers reflecting different pathophysiological axes such as myocardial injury (high-sensitivity troponin T (hsTnT)) and stretch (N-terminal pro-brain natriuretic peptide (NT-proBNP)).We prospectively studied 268 normotensive pulmonary embolism patients included in a single-centre cohort study.Patients with an adverse 30-day outcome (5.6%) had higher copeptin levels than patients with a favourable course (median (interquartile range) 51.8 (21.6–90.8) versus 13.2 (5.9–39.3) pmol·L−1; p…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtymedicine.drug_classVentricular Dysfunction Right030204 cardiovascular system & hematologyRisk AssessmentCohort Studies03 medical and health sciencesCatecholamines0302 clinical medicineCopeptinTroponin TInterquartile rangeInternal medicineNatriuretic Peptide BrainmedicineNatriuretic peptideHumansProspective StudiesProspective cohort studyAgedTroponin Tbusiness.industryGlycopeptidesMiddle AgedPrognosismedicine.diseaseRespiration ArtificialCardiopulmonary ResuscitationPeptide Fragments3. Good healthPulmonary embolism030228 respiratory systemCardiologyFemalePulmonary EmbolismRisk assessmentbusinessBiomarkersCohort studyEuropean Respiratory Journal
researchProduct

Anticoagulant drugs in noncompaction: A mandatory therapy?

2008

BACKGROUND: Noncompaction of left ventricular myocardium is a rare congenital cardiomyopathy resulting from an incomplete myocardial morphogenesis that leads to the persistence of the embryonic myocardium. This condition is characterized by a thin compacted epicardial and an extremely thickened endocardial layer with prominent trabeculations and deep intertrabecular recesses. It is not clear, in noncompaction of myocardium, whether intertrabecular recesses could be responsible for thrombi formation and thromboembolic complications. METHODS: The prevalence of stroke and echocardiographic finding of thrombus was evaluated in a continuous series of 229 patients (men and women) affected by nonc…

MaleRegistrieTime FactorsEmbolismAdministration OralHeart VentricleRisk FactorsRegistriesStrokeIschemic strokeAnticoagulantCongenital cardiomyopathyGeneral MedicineMiddle AgedStrokeAnticoagulant drugsCardiologycardiovascular systemFemaleAnticoagulant drugs noncompactionCardiomyopathiesCardiology and Cardiovascular MedicineHumanAdultHeart Defects Congenitalmedicine.medical_specialtyStroke etiologyTime Factormedicine.drug_classIsolated left ventricular noncompactionHeart Ventriclesanticoagulant; embolism; ischemic stroke; Isolated left ventricular noncompactionInternal medicineThromboembolismmedicineHumanscardiovascular diseasesThrombusNoncompactionCardiomyopathiebusiness.industryRisk FactorAnticoagulantAnticoagulantsInfantmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareEmbolismIschemic strokeThrombuLeft ventricular myocardiumbusiness
researchProduct

Impact of pulmonary embolism on in-hospital mortality of patients with ischemic stroke

2020

Pulmonary embolism (PE) is a frequent complication in immobile stroke patients and an important cause of death in stroke patients. We aimed to investigate predictors of PE and the impact of PE on survival of ischemic stroke patients.Patients were selected by screening the German nationwide inpatient sample (2005-2017) for ischemic stroke (ICD-code I63) and stratified for occurrence of PE (ICD-code I26). Impact of PE on mortality and predictors for PE in ischemic stroke patients were analysed.Overall, 2,914,546 patients were hospitalized due to ischemic stroke (50.5% females; 69.3% aged ≥70 years) in Germany 2005-2017. Among these, 0.4% had PE and 7.2% died during hospitalization. In-hospita…

MaleResuscitationmedicine.medical_specialtymedicine.medical_treatmentBrain Ischemia03 medical and health sciences0302 clinical medicineGermanyInternal medicineHumansMedicineHospital Mortalitycardiovascular diseases030212 general & internal medicineAgedIschemic StrokeCause of deathIn hospital mortalitybusiness.industryMortality rateThrombolysismedicine.diseasePulmonary embolismStrokeNeurologyIschemic strokeCardiologyFemaleNeurology (clinical)Pulmonary EmbolismbusinessComplication030217 neurology & neurosurgeryJournal of the Neurological Sciences
researchProduct

Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normali…

2012

Subtherapeutic international normalized ratio (INR) is frequently encountered in clinical practice, and patients with high-risk atrial fibrillation (AF) and with mechanical heart valve (MHV) with inadequate anticoagulation may be exposed to an increased risk of thromboembolic events (TE). However, there are no prospective data evaluating this risk. Consecutive patients with a history of stable anticoagulation, but with a subtherapeutic INR, were prospectively included. Data on use and dose of low-molecular weight heparin (LMWH) bridging therapy were collected. The incidence of objectively confirmed TE and of major bleeding events within 90 days after the index INR was assessed. Five hundred…

MaleRiskmedicine.medical_specialtyPopulationvenous thromboembolismHemorrhageComorbidityThrombophiliaFollow-Up StudiePostoperative ComplicationsInternal medicineThromboembolismAtrial FibrillationmedicineHumansThrombophiliaProspective StudiesInternational Normalized RatioeducationProspective cohort studyAgedAged 80 and overHeart Valve Prosthesis Implantationeducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceMedicine (all)WarfarinAnticoagulantAnticoagulantsAtrial fibrillationHematologyHeparin Low-Molecular-WeightMiddle Agedmedicine.diseaseConfidence intervalSurgeryProspective StudieHeart Valve ProsthesiHeart Valve ProsthesisFemalePostoperative ComplicationWarfarinbusinessCohort studymedicine.drugFollow-Up StudiesHuman
researchProduct

Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

2017

AbstractPatients with intermediate-risk pulmonary embolism (PE) may, depending on the method and cut-off values used for definition, account for up to 60% of all patients with PE and have an 8% or higher risk of short-term adverse outcome. Although four non-vitamin K-dependent direct oral anticoagulants (NOACs) have been approved for the treatment of venous thromboembolism, their safety and efficacy as well as the optimal anticoagulation regimen using these drugs have not been systematically investigated in intermediate-risk PE. Moreover, it remains unknown how many patients with intermediate-high-risk and intermediate-low-risk PE were included in most of the phase III NOAC trials. The ongo…

MaleRiskmedicine.medical_specialtypulmonary embolismDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentHemorrhageintermediate risk030204 cardiovascular system & hematologyDabigatran03 medical and health sciencesYoung Adult0302 clinical medicineRecurrenceInternal medicineGermanymedicineHumansdabigatran030212 general & internal medicineProspective StudiesProspective cohort studySurvival analysisvenous thromboembolism recurrencebusiness.industryHeparinAnticoagulantsHematologyThrombolysisHeparinReference Standardsmedicine.diseaseThrombosisSurvival Analysis3. Good healthPulmonary embolismright ventricular functionRegimenTreatment OutcomeResearch Designmajor bleedingAcute Diseasedabigatran; intermediate risk; major bleeding; pulmonary embolism; right ventricular function; venous thromboembolism recurrenceFemalebusinessmedicine.drugFollow-Up Studies
researchProduct

Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study

2015

Abstract Background It is well known that atrial fibrillation (AF) and chronic kidney disease (CKD) are associated with a higher risk of stroke, and new evidence links AF to cognitive impairment, independently from an overt stroke (CI). Our aim was to investigate, assuming an underlying role of atrial microembolism, the impact of CI and CKD in elderly hospitalized patients with AF. Methods We retrospectively analyzed the data collected on elderly patients in 66 Italian hospitals, in the frame of the REPOSI project. We analyzed the clinical characteristics of patients with AF and different degrees of CI. Multivariate logistic analysis was used to explore the relationship between variables an…

MaleSettore MED/09 - Medicina InternaREPOSI studyKidneyDisability EvaluationRetrospective StudieRisk Factorshospitalized patientAtrial Fibrillation80 and overOdds RatioLS4_4Renal InsufficiencyChronicMultivariate AnalysiStrokeAged 80 and overMedicine (all)BrainAtrial fibrillationStrokeFemaleatrial microembolismHumanGlomerular Filtration Ratemedicine.medical_specialtySocio-culturaleRenal functionelderlyCognition DisorderInternal medicineThromboembolismmedicineInternal MedicineHumansRenal insufficiency chronicHeart AtriaIntensive care medicineAged; Anticoagulants; Atrial fibrillation; Dementia; Renal insufficiency chronic; Stroke; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Brain; Cognition Disorders; Dementia; Disability Evaluation; Female; Glomerular Filtration Rate; Heart Atria; Humans; Kidney; Male; Multivariate Analysis; Odds Ratio; Renal Insufficiency Chronic; Retrospective Studies; Risk Factors; Stroke; ThromboembolismAgedRetrospective Studiesbusiness.industryRisk FactorSettore MED/09 - MEDICINA INTERNAAnticoagulantAnticoagulantsRetrospective cohort studyOdds ratiomedicine.diseaseAtrial fibrillationBlood pressureHeart failureMultivariate AnalysisAged Anticoagulants Atrial fibrillation Dementia Renal insufficiency chronic Stroke.Aged; Anticoagulants; Atrial fibrillation; Dementia; Renal insufficiency chronic; Strokeatrial microembolism; elderly; hospitalized patients; REPOSI study;DementiabusinessCognition DisordersKidney diseaseAged; Anticoagulants; Atrial fibrillation; Dementia; Renal insufficiency chronic; Stroke; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Brain; Cognition Disorders; Dementia; Disability Evaluation; Female; Glomerular Filtration Rate; Heart Atria; Humans; Kidney; Male; Multivariate Analysis; Odds Ratio; Renal Insufficiency Chronic; Retrospective Studies; Risk Factors; Stroke; Thromboembolism; Internal Medicine; Medicine (all)
researchProduct

Early Seizures After Acute Stroke: A Study of 1,640 Cases

1994

We evaluated prospectively the occurrence of seizures within 15 days of a first stroke or transient ischemic episode in 1,640 patients to study relation between seizures and type of stroke. Seizures occurred in 90 patients (5.4%), including 36 (4.4%) of 814 with infarct owing to atheroma, 21 (16.6%) of 126 with infarct owing to cardiogenic embolus, 3 (1%) of 273 owing to lacunar infarct, 5 (1.9%) of 259 owing to transient ischemic attack (TIA), 21 (16.2%) of 129 owing to supratentorial hematoma, and 4 (16.6%) of 24 owing to subarachnoid hemorrhage. Thirteen (14.6%) of 89 subcortical infarcts were associated with seizures. Seizures were the initial sign of stroke in 80 (89%) of 90 cases and …

MaleSubarachnoid hemorrhageComorbidityCentral nervous system diseaseHematomaEmbolusmedicineHumansProspective StudiesRegistriescardiovascular diseasesProspective cohort studyStrokeAgedAged 80 and overEpilepsybusiness.industryVascular diseaseIncidenceCerebral InfarctionIntracranial Embolism and ThrombosisMiddle AgedSubarachnoid HemorrhageIntracranial Arteriosclerosismedicine.diseaseCerebrovascular DisordersNeurologyEmbolismIschemic Attack TransientAnesthesiacardiovascular systemRegression AnalysisFemaleFranceNeurology (clinical)businessEpilepsia
researchProduct